Tags

Type your tag names separated by a space and hit enter

Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
Int J Clin Pharmacol Ther. 2005 Nov; 43(11):527-35.IJ

Abstract

OBJECTIVE

Aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension. This study investigated the interaction profile of aliskiren, which is of clinical importance because hypertensive patients often require concomitant drug therapy for associated comorbidities.

METHODS

Four separate studies investigated the pharmacokinetic interaction between single oral doses of aliskiren and lovastatin, atenolol, celecoxib or cimetidine, respectively. All studies involved healthy male volunteers aged 18-45 years. In 3 studies, subjects (n = 15 in each study) received single doses of aliskiren 150 mg alone, the test drug alone (lovastatin 40 mg, atenolol 100 mg or celecoxib 200 mg), or both drugs in combination, according to a 3-period crossover design. In the cimetidine study (n = 12), aliskiren 150 mg was administered alone or concomitantly with cimetidine 800 mg according to a two-period crossover design. Plasma concentrations of aliskiren and test drugs were determined by liquid chromatography and mass spectrometry methods. Pharmacokinetic parameters were derived from these data.

RESULTS

Mean AUC and t1/2 for aliskiren were not significantly changed by lovastatin, atenolol or celecoxib (< 10% difference between treatments). Aliskiren mean Cmax was not affected by either lovastatin or atenolol, although a non-significant 36% increase was observed with celecoxib. Modest, non-significant increases in aliskiren systemic availability followed coadministration with cimetidine (aliskiren mean AUC, Cmax and t1/2 increased by 17%, 19% and 15%, respectively). Aliskiren coadministration had no significant effect on the disposition of lovastatin, atenolol or celecoxib.

CONCLUSIONS

Overall, single doses of aliskiren showed no evidence of clinically important pharmacokinetic interactions with lovastatin, atenolol, celecoxib or cimetidine.

Authors+Show Affiliations

Drug Disposition Consultants, Lörrach, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16300168

Citation

Dieterle, W, et al. "Pharmacokinetic Interactions of the Oral Renin Inhibitor Aliskiren With Lovastatin, Atenolol, Celecoxib and Cimetidine." International Journal of Clinical Pharmacology and Therapeutics, vol. 43, no. 11, 2005, pp. 527-35.
Dieterle W, Corynen S, Vaidyanathan S, et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther. 2005;43(11):527-35.
Dieterle, W., Corynen, S., Vaidyanathan, S., & Mann, J. (2005). Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. International Journal of Clinical Pharmacology and Therapeutics, 43(11), 527-35.
Dieterle W, et al. Pharmacokinetic Interactions of the Oral Renin Inhibitor Aliskiren With Lovastatin, Atenolol, Celecoxib and Cimetidine. Int J Clin Pharmacol Ther. 2005;43(11):527-35. PubMed PMID: 16300168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. AU - Dieterle,W, AU - Corynen,S, AU - Vaidyanathan,S, AU - Mann,J, PY - 2005/11/23/pubmed PY - 2006/1/27/medline PY - 2005/11/23/entrez SP - 527 EP - 35 JF - International journal of clinical pharmacology and therapeutics JO - Int J Clin Pharmacol Ther VL - 43 IS - 11 N2 - OBJECTIVE: Aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension. This study investigated the interaction profile of aliskiren, which is of clinical importance because hypertensive patients often require concomitant drug therapy for associated comorbidities. METHODS: Four separate studies investigated the pharmacokinetic interaction between single oral doses of aliskiren and lovastatin, atenolol, celecoxib or cimetidine, respectively. All studies involved healthy male volunteers aged 18-45 years. In 3 studies, subjects (n = 15 in each study) received single doses of aliskiren 150 mg alone, the test drug alone (lovastatin 40 mg, atenolol 100 mg or celecoxib 200 mg), or both drugs in combination, according to a 3-period crossover design. In the cimetidine study (n = 12), aliskiren 150 mg was administered alone or concomitantly with cimetidine 800 mg according to a two-period crossover design. Plasma concentrations of aliskiren and test drugs were determined by liquid chromatography and mass spectrometry methods. Pharmacokinetic parameters were derived from these data. RESULTS: Mean AUC and t1/2 for aliskiren were not significantly changed by lovastatin, atenolol or celecoxib (< 10% difference between treatments). Aliskiren mean Cmax was not affected by either lovastatin or atenolol, although a non-significant 36% increase was observed with celecoxib. Modest, non-significant increases in aliskiren systemic availability followed coadministration with cimetidine (aliskiren mean AUC, Cmax and t1/2 increased by 17%, 19% and 15%, respectively). Aliskiren coadministration had no significant effect on the disposition of lovastatin, atenolol or celecoxib. CONCLUSIONS: Overall, single doses of aliskiren showed no evidence of clinically important pharmacokinetic interactions with lovastatin, atenolol, celecoxib or cimetidine. SN - 0946-1965 UR - https://www.unboundmedicine.com/medline/citation/16300168/Pharmacokinetic_interactions_of_the_oral_renin_inhibitor_aliskiren_with_lovastatin_atenolol_celecoxib_and_cimetidine_ DB - PRIME DP - Unbound Medicine ER -